dc.contributor.author
Zickler, Daniel
dc.contributor.author
Schindler, Ralf
dc.contributor.author
Willy, Kevin
dc.contributor.author
Martus, Peter
dc.contributor.author
Pawlak, Michael
dc.contributor.author
Storr, Markus
dc.contributor.author
Hulko, Michael
dc.contributor.author
Boehler, Torsten [u.a.]
dc.date.accessioned
2018-06-08T10:35:12Z
dc.date.available
2017-03-15T09:40:09.317Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/20693
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-23993
dc.description.abstract
Background To increase the removal of middle-sized uremic toxins a new
membrane with enhanced permeability and selectivity, called Medium Cut-Off
membrane (MCO-Ci) has been developed that at the same time ensures the
retention of albumin. Because many middle-sized substances may contribute to
micro-inflammation we hypothesized that the use of MCO-Ci influences the
inflammatory state in hemodialysis patients. Methods The randomized crossover
trial in 48 patients compared MCO-Ci dialysis to High-flux dialysis of 4 weeks
duration each plus 8 weeks extension phase. Primary endpoint was the gene
expression of TNF-α and IL-6 in peripheral blood mononuclear cells (PBMCs),
secondary endpoints were plasma levels of specified inflammatory mediators and
cytokines. Results After four weeks of MCO-Ci the expression of TNF-α mRNA
(Relative quantification (RQ) from 0.92 ± 0.34 to 0.75 ± 0.31, -18.5%,
p<0.001)-α and IL-6 mRNA (RQ from 0.78 ± 0.80 to 0.60 ± 0.43, -23.1%, p<0.01)
was reduced to a significantly greater extent than with High-flux dialyzers
(TNF mRNA-RQ: -14.3%; IL-6 mRNA-RQ: -3.5%). After retransformation of
logarithmically transformed data, measurements after MCO were reduced to 82%
of those after HF (95% CI 74%–91%). 4 weeks use of MCO-Ci resulted in long-
lasting change in plasma levels of several cytokines and other substances with
a significant decrease for sTNFR1, kappa and lambda free light chains, urea
and an increase for Lp-PLA2 (PLA2G7) compared to High-flux. Albumin levels
dropped significantly after 4 weeks of MCO dialysis but increased after
additional 8 weeks of MCO dialysis. Twelve weeks treatment with MCO-Ci was
well tolerated regarding the number of (S)AEs. In the extension period levels
of CRP, TNF-α-mRNA and IL-6 mRNA remained stable in High-flux as well as in
MCO-Ci. Conclusions MCO-Ci dialyzers modulate inflammation in chronic HD
patients to a greater extent compared to High-flux dialyzers. Transcription of
pro-inflammatory cytokines in peripheral leukocytes is markedly reduced and
removal of soluble mediators is enhanced with MCO dialysis. Serum albumin
concentrations stabilize after an initial drop. These results encourage
further trials with longer treatment periods and clinical endpoints.
de
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis
Patients—A Randomized Controlled Clinical Trial
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
PLoS ONE. - 12 (2017). 1, Artikel Nr. e0169024
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0169024
dcterms.bibliographicCitation.url
http://dx.doi.org/10.1371/journal.pone.0169024
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000026636
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000007901
dcterms.accessRights.openaire
open access